FDA Monoclonal Antibody Therapy Update

Angie Szumlinski News

The U.S. government is no longer distributing the monoclonal antibody therapy bamlanivimab due to the sustained increase in coronavirus variants in the United States. The FDA has determined that this monoclonal antibody therapy may not produce the desired effects with the widely spreading variants of the virus. However, when administered with etesevimab, another monoclonal antibody treatment also developed by Eli …


Bamlanivimab Prevented COVID-19 in BLAZE-2 Trial

Angie Szumlinski Health, Studies

Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff in long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The 965 participants who tested negative for the SARS-CoV-2 virus at baseline (299 residents and 666 staff) were included in the analysis of primary and key secondary endpoints for assessing prevention, while the 132 participants …